6533b81ffe1ef96bd12779c1
RESEARCH PRODUCT
A randomized study of tucatinib (ONT-380) vs. placebo in combination with capecitabine and trastuzumab in patients with pretreated HER2-pos. metastatic breast cancer: HER2CLIMB
R WeideV MüllerTw Park-simonChristoph MundhenkeMartina SchmidtMattea ReinischS. LoiblJ HuoberTanja FehmC SalatEp Winersubject
Oncologymedicine.medical_specialtybusiness.industrymedicine.diseasePlaceboMetastatic breast cancerlaw.inventionCapecitabine03 medical and health sciences0302 clinical medicineRandomized controlled triallawTrastuzumab030220 oncology & carcinogenesisInternal medicinemedicineIn patientbusiness030217 neurology & neurosurgerymedicine.drugyear | journal | country | edition | language |
---|---|---|---|---|
2018-09-20 | Geburtshilfe und Frauenheilkunde |